Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales.
A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. The work here considers the impact of prison vaccination on the incidence and prevalence of hepatitis B virus (HBV) in the injecting drug user (IDU) population of England and Wales. A dynamic model of the transmission of HBV in IDUs is developed with key model assumptions and parameters being subject to sensitivity analyses. The base case model (that assumes that the vaccination coverage on prison reception is 5% in 2002, 10% in 2003 and then increases linearly up to 50% of prison receptions being vaccinated by 2006) predicts that the incidence of HBV in IDUs might be reduced by almost 80% in 12 years, and the HBV prevalence (IDUs ever infected by HBV) may be reduced from approximately 18% in 2002 to 7% in 2015. The model presented here demonstrates that HBV vaccination on prison reception can have a significant impact on the prevalence and incidence of HBV in the IDU population over time.
Sutton
A J
AJ
Modelling and Economics Unit, Health Protection Agency, Centre for Infections, 61 Colindale Ave, Colindale, London NW9 5EQ, UK. andrew.sutton@hpa.org.uk
Gay
N J
NJ
Edmunds
W J
WJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D004739:England / Q000453:epidemiology; D006509:Hepatitis B / Q000453:epidemiology / Q000635:transmission*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D008962:Models, Theoretical; D011330:Prisons; D015819:Substance Abuse, Intravenous / Q000150:complications*; D014611:Vaccination; D014852:Wales / Q000453:epidemiology
D017325:Hepatitis B Vaccines